Y-Intercept (HK)’s Eli Lilly LLY Stock Holding History

Y-Intercept (HK)’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.97M	Sell	8,310 -24,672	-75%	-$25.2M	0.2%	90
2026 Q1	$30.3M	Buy	+32,982	New	+$33.4M	0.58%	5
2025 Q2	–	Sell	-2,295	Closed	-$1.9M	–	1856
2025 Q1	$1.9M	Sell	2,295 -3,065	-57%	-$2.55M	0.13%	204
2024 Q4	$4.14M	Sell	5,360 -10,531	-66%	-$8.72M	0.28%	72
2024 Q3	$14.1M	Buy	+15,891	New	+$14.3M	0.86%	5
2024 Q1	–	Sell	-2,298	Closed	-$1.34M	–	1589
2023 Q4	$1.34M	Buy	+2,298	New	+$1.34M	0.12%	220
2022 Q2	–	Sell	-2,115	Closed	-$606K	–	1054
2022 Q1	$606K	Buy	+2,115	New	+$544K	0.14%	205
2021 Q4	–	Sell	-3,786	Closed	-$875K	–	745
2021 Q3	$875K	Buy	+3,786	New	+$934K	0.16%	207
2021 Q2	–	Sell	-10,869	Closed	-$2.02M	–	769
2021 Q1	$2.02M	Buy	+10,869	New	+$2.13M	0.54%	30

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Y-Intercept (HK)'s LLY Position: Q2 2026 in Review

Y-Intercept (HK) reduced its Eli Lilly (LLY) stake by 75% in Q2 2026, selling an estimated $25.2M and leaving 8,310 shares worth $9.97M. The position accounts for 0.2% of the portfolio, ranked #90.

Y-Intercept (HK) first reported a position in LLY in Q1 2021 and has held it in 9 quarters since. The position peaked at $30.3M in Q1 2026. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

Y-Intercept (HK) held 8,310 shares of Eli Lilly worth $9.97M as of Q2 2026.
Y-Intercept (HK) sold 24,672 Eli Lilly shares in Q2 2026, an estimated $25.2M.
Eli Lilly made up 0.2% of Y-Intercept (HK)'s portfolio in Q2 2026, its #90 holding.
Y-Intercept (HK) first reported a position in Eli Lilly in Q1 2021 and has held it in 9 quarters since.
Y-Intercept (HK)'s Eli Lilly position peaked at $30.3M in Q1 2026.
4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.